Eli Lilly and Company (LLY)
Return on total capital
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 7,040,500 | 6,573,900 | 7,669,100 | 6,632,000 | 7,138,000 | 6,878,900 | 6,560,800 | 7,069,500 | 6,495,200 | 7,132,200 | 7,330,100 | 7,381,300 | 7,589,500 | 6,790,200 | 6,776,600 | 6,621,400 | 9,347,100 | 8,580,500 | 8,525,100 | 7,025,000 |
Long-term debt | US$ in thousands | 18,320,800 | 17,923,600 | 18,158,400 | 18,880,500 | 14,737,500 | 14,143,800 | 14,692,000 | 15,152,900 | 15,346,400 | 15,522,400 | 14,736,600 | 16,199,600 | 16,586,600 | 16,334,600 | 15,064,400 | 13,982,300 | 13,817,900 | 13,662,200 | 13,717,600 | 13,610,200 |
Total stockholders’ equity | US$ in thousands | 10,771,900 | 11,220,400 | 11,063,800 | 11,190,400 | 10,649,800 | 10,070,100 | 8,544,700 | 9,330,800 | 8,979,200 | 7,757,000 | 6,444,400 | 6,898,700 | 5,641,600 | 4,826,900 | 4,092,900 | 3,078,800 | 2,606,900 | 3,382,500 | 2,780,500 | 2,480,300 |
Return on total capital | 24.20% | 22.56% | 26.24% | 22.05% | 28.12% | 28.41% | 28.23% | 28.87% | 26.70% | 30.64% | 34.61% | 31.96% | 34.14% | 32.09% | 35.37% | 38.81% | 56.91% | 50.34% | 51.67% | 43.66% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $7,040,500K ÷ ($18,320,800K + $10,771,900K)
= 24.20%
Lilly(Eli) & Co's return on total capital has shown a downward trend over the past eight quarters. The return on total capital was 28.68% in Q4 2023, decreasing from 29.83% in Q3 2023, and continuing the declining trend from the previous quarters. The company's return on total capital was highest at 34.21% in Q2 2022 and has gradually decreased since then.
This decreasing trend in return on total capital may indicate potential challenges in generating profits relative to the total capital employed by the company. It is essential for Lilly(Eli) & Co to closely monitor and improve its operational efficiency and capital allocation strategies to enhance its return on total capital in the future. Additionally, further analysis of the company's financial statements and operational performance may provide insights into the factors driving the fluctuation in return on total capital.
Peer comparison
Dec 31, 2023